Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC trimmed its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 2.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,437,305 shares of the medical research company's stock after selling 57,175 shares during the period. Champlain Investment Partners LLC owned approximately 1.32% of Exact Sciences worth $136,952,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Marshall Wace LLP acquired a new stake in Exact Sciences during the fourth quarter worth about $5,685,000. Advisors Capital Management LLC purchased a new position in Exact Sciences in the fourth quarter valued at $515,000. Sterling Capital Management LLC raised its position in shares of Exact Sciences by 40.6% in the fourth quarter. Sterling Capital Management LLC now owns 7,759 shares of the medical research company's stock worth $436,000 after acquiring an additional 2,242 shares during the period. Harbert Fund Advisors Inc. acquired a new stake in shares of Exact Sciences during the 4th quarter valued at about $702,000. Finally, Kennedy Capital Management LLC raised its holdings in Exact Sciences by 10.2% in the 4th quarter. Kennedy Capital Management LLC now owns 147,459 shares of the medical research company's stock worth $8,286,000 after purchasing an additional 13,600 shares during the period. 88.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of recent analyst reports. Mizuho initiated coverage on Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price on the stock. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Piper Sandler lowered their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Guggenheim reissued a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a research note on Friday, April 11th. Finally, Royal Bank of Canada started coverage on Exact Sciences in a research report on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 price target for the company. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $69.25.

Exact Sciences Stock Performance

NASDAQ EXAS traded up $1.26 during trading hours on Tuesday, hitting $44.36. The company had a trading volume of 766,778 shares, compared to its average volume of 2,604,052. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The company has a market cap of $8.24 billion, a PE ratio of -7.92 and a beta of 1.14. The business has a 50 day moving average of $45.73 and a 200-day moving average of $54.69.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. As a group, equities research analysts expect that Exact Sciences Co. will post -0.58 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.